Christopher Komanski, MD
Ophthalmology · Asheville, NCNPI 1558781856
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $92,090 of the $111,193 with a category attached, or 82.8%. Genentech USA, Inc. accounts for 94.0% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2023 at $49,846 and has fallen 99.0% since, to $503 in 2025. Among ophthalmology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 134 payments — averaging $829.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$105K
- Apellis Pharmaceuticals, Inc.$4K
- Novartis$1K
- Regeneron$647
- AbbVie$444
- Regeneron Healthcare Solutions, Inc.$260
- plus $367 from 6 others
What the payments were for
- Consulting fees$8,0737%
- Speaking & faculty fees$92,09083%
- Travel & lodging$6,0545%
- Food & beverage$4,9764%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 72 | $104,507 |
| Apellis Pharmaceuticals, Inc. | 24 | $3,781 |
| Novartis | 6 | $1,187 |
| Regeneron | 4 | $647 |
| AbbVie(2 entities) | 13 | $444 |
| Regeneron Healthcare Solutions, Inc. | 8 | $260 |
| Alcon | 1 | $155 |
| Genentech, Inc. | 1 | $121 |
| Astellas Pharma US Inc | 2 | $44 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $22 |
| Sight Sciences, Inc. | 1 | $14 |
| Alimera Sciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$111,193 in reported general payments places this provider in the 95th percentile of 588 ophthalmology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 183 | $9,163 |
| Brimonidine Tartrate | 43 | $3,209 |
| Ketorolac Tromethamine | 87 | $1,994 |
| Difluprednate | 16 | $1,686 |
| Atropine Sulfate | 33 | $1,223 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 45 | $771 |
| Timolol Maleate | 46 | $484 |
| MoxifloxacinMoxifloxacin Hcl | 21 | $422 |
| Latanoprost | 16 | $369 |
| Prednisone | 16 | $205 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Asheville
- Preeya GuptaRaleigh$1.8M
- Julie WoodwardDurham$1M
- Rajiv ShahWinston Salem$909K
- Lejla VajzovicDurham$681K
- Karl StonecipherGreensboro$653K
- Terry KimDurham$605K
- Keith WalterWinston Salem$397K
- Leon HerndonDurham$230K
- Thomas MundorfCharlotte$220K
- Glenn JaffeDurham$218K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.